Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT03634241 2026-04-16

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

45 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07223424 2026-04-16

PSI-Immune

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

880 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT03236935 2026-04-09

Phase Ib of L-NMMA and Pembrolizumab

Phase 1 Completed

12 enrolled 15 charts

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, DNA Repair-Deficiency Disorders

NCT04317534 2026-04-08

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

244 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06745882 2026-04-02

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

318 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05669846 2026-03-23

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

26 enrolled

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04253964 2026-03-19

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

105 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04007744 2026-03-18

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

36 enrolled

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT02818920 2026-03-17

TOP 1501

35 enrolled 11 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Carcinoma, Non-Small-Cell Lung

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07017829 2026-03-11

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

28 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02858869 2026-03-09

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

Phase 1 Completed

25 enrolled 14 charts

CNSDermatologicThoracic

Uveal Melanoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06219174 2026-03-06

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)

Phase 1/2 Suspended

45 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03774732 2026-02-25

NIRVANA-LUNG

327 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02422381 2026-02-18

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

16 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03559049 2026-02-12

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Phase 1/2 Terminated

25 enrolled 11 charts

Phase EARLY_PHASE1 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05493566 2026-02-12

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

15 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06731270 2026-02-12

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

20 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07360743 2026-02-10

META-1

275 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04297605 2026-02-09

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

Phase 1 Recruiting

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07394062 2026-02-06

ALCG-01

Recruiting

400 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03436056 2026-01-29

PRIMING

Phase 1 Terminated

2 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

DermatologicGenitourinaryHead & NeckThoracic

18 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT02432963 2026-01-28

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

Phase 1 Active not recruiting

11 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Carcinoma, Hepatocellular, Melanoma, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Triple Negative Breast Neoplasms

NCT04166487 2026-01-21

Plasma-Adapted First-Line Pembro In NSCLC

Phase 2 Active not recruiting

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03003468 2026-01-20

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

Phase 1/2 Completed

35 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT03225664 2026-01-16

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

37 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02638090 2025-12-22

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)

120 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06908993 2025-12-17

COMET

Phase 3 Recruiting

133 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02621398 2025-12-16

Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer

Phase 1 Completed

23 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT05570825 2025-12-04

SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03137771 2025-11-25

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

218 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT02955290 2025-11-10

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

51 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03049618 2025-10-22

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

42 enrolled 40 charts

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT02444741 2025-10-09

Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

126 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07207395 2025-10-06

A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06822543 2025-09-29

TROPICAL-1

Phase 3 Active not recruiting

46 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04547504 2025-09-17

PERSEE

349 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03307759 2025-09-15

SABRseq

Phase 1 Terminated

13 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT06364917 2025-09-03

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

24 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05782361 2025-08-20

POTENT

Phase 1 Recruiting

19 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02998567 2025-08-17

HyPeR

Phase 1 Recruiting

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02681549 2025-08-07

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

41 enrolled 20 charts

CNSDermatologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05691829 2025-07-29

IRRADIATE-Lung

Phase 2 Terminated

19 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06579196 2025-07-24

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

Phase 1/2 Recruiting

45 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05894889 2025-07-23

Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC

70 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06902272 2025-07-22

DNA-PREDICT

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06951399 2025-07-22

Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer